Loxo Oncology announces larotrectinib clinical update in patients with TRK fusion cancers
Loxo Oncology announced updated clinical data for larotrectinib, an investigational oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers. The update included approximately one year of additional follow-up for the 55 patients described in the NEJM. October 21, 2018